HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Timothy Still, Chairman of Volition Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his ...

HENDERSON, Nev., Oct. 31, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has published a report, from its 'NETs in sepsis management' symposium at ESICM Lives 2024 last month, which concluded that Nu.Q® NETs could be used to predict patients at greater risk of deteriorating from sepsis.The symposium explored research findings from three large, independent studies carried out at centers of excellence in France, Germany, and the Netherlands, i ...

Given the extensive size and scope of the three independent studies on the potential use of Nu.Q® NETs in sepsis management, which included over 3000 patients and more than 14,000 patient samples, the webinar aims to provide stakeholders with a comprehensive understanding of the data and offer insights into how Volition's nucleosome quantification technology could be used in clinical practice. The webinar takes place on Monday, October 21, at 10:00 AM U.S. Eastern Time and will include updates from Volition ...

HENDERSON, Nev., Oct. 3, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024, during which experts from across the globe will present findings from large, independent studies regarding the potential of using Nu.Q® NETs to determine a 'treatable trait' to enhance sepsis management. The session, entitled 'NETs: Casting a new light on sepsis management', will take place at 12 ...

HENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Committee. Dr. Rubin has over 20 years' experience within the life sciences sector, leading healthcare innovation and commercialization strategies for a wide range of ...

VolitionRx Limited (NYSE:VNRX) Q2 2024 Earnings Conference Call August 15, 2024 8:30 AM ET Company Participants Louise Batchelor - Chief Marketing and Communications Officer Cameron Reynolds - President and CEO Terig Hughes - CFO Andrew Retter - CMO Gael Forterre - CCO Conference Call Participants Bruce Jackson - The Benchmark Company Ilya Zubkov - Freedom Broker Steven Ralston - Zacks Small-Cap Research Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the VolitionRx Li ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VolitionRx Limited (Exact name of registrant as specified in its charter) | --- | |------------------------------------| | Delaware | | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2024 | --- | --- | --- | --- | |------------------------------------------|-----------------------------------------------------|----------------------|--------------------------| | (Exact name | VolitionRx Limited of registrant as specified | in its | charter) | | Delaware | 001-368 ...

Conference call to discuss financial and operational results scheduled for Thursday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Aug. 14, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the second quarter of 2024. Volition management will host a conference call tomorrow, August 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be fo ...

$7 million upfront with up to an additional $14.5 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants HENDERSON, Nev., Aug. 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of 12,727,273 shares of its common stock (or common stock equivalents in lieu thereof) and milestone-linked warrants ...